SCHEMBL2697408

SCHEMBL2697408

CCC(CC)N1CCCC2(CCN(Cc3ccc(C(=O)N(Cc4ncc[nH]4)Cc4ncc[nH]4)cc3)CC2)C1

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 3/20 0.72
OPRD1 P41143 5/20 0.45
CTSD P07339 1/20 0.38
KDM1A O60341 1/20 0.38
MAOB P27338 1/20 0.38
RCOR1 Q9UKL0 1/20 0.38
CYP3A4 P08684 9/20 0.37
CYP2C9 P11712 7/20 0.37
CYP2D6 P10635 5/20 0.37
CYP2C19 P33261 4/20 0.37
CYP1A2 P05177 3/20 0.37
OPRM1 P35372 4/20 0.37
ALDH1A1 P00352 3/20 0.36
KCNH2 Q12809 2/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.35
CASP1 P29466 1/20 0.35
OPRK1 P41145 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2695491 0.96 CXCR4 (0.75) CXCR4OPRD1CTSDKDM1AMAOB
SCHEMBL2695164 0.93 CXCR4 (0.73) CXCR4OPRD1CTSDKDM1AMAOB
SCHEMBL2693671 0.92 CXCR4 (0.69) CXCR4OPRD1KDM1AMAOBRCOR1
SCHEMBL1794672 0.91 CXCR4 (0.75) CXCR4OPRD1CTSDKDM1AMAOB
SCHEMBL2695095 0.88 CXCR4 (0.65) CXCR4OPRD1CTSDKDM1AMAOB
SCHEMBL2692361 0.88 CXCR4 (0.71) CXCR4OPRD1CTSDKDM1AMAOB
SCHEMBL1793784 0.86 CXCR4 (0.74) CXCR4OPRD1CTSDKDM1AMAOB
SCHEMBL2693586 0.86 CXCR4 (0.93) CXCR4OPRD1KDM1AMAOBRCOR1
SCHEMBL2695818 0.85 CXCR4 (0.62) CXCR4OPRD1CTSD
SCHEMBL1795594 0.85 CXCR4 (0.80) CXCR4OPRD1CTSDKDM1AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8519124-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 US claimed
EP-1961744-B1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-04-17 EP claimed
US-8519124-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 US disclosed
EP-1961744-B1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-04-17 EP disclosed
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-08-16 US disclosed
US-8168783-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-05-01 US disclosed
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD., (JP) 2009-07-02 US disclosed
EP-1961744-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2008-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885OPRD1 2003/4885CTSD 3136/4885
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF CXCR4, CXCR3, CXCR1 CXCR4 1/4885OPRD1 1440/4885CTSD 3050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.